surmount-1 tirzepatide weight loss nondiabetic FDA Grants a New Indication for Obesity Management SURMOUNT-1
Description
2023;24(7):e13568
Both carry warnings about pancreatitis, gallbladder problems, and thyroid tumors (based on animal studies)
A clean-label patch offers a low-commitment trial before pursuing care
Additionally, increased thirst, frequent urination, or unexplained hunger despite taking tirzepatide could suggest inadequate diabetes control or other metabolic issues
This isnt a failure of the drug its a reflection of what obesity actually is
We'll discuss your health history, understand your weight loss goals, and determine if this treatment is the right fit for you
